Cognitive burden of anticholinergic medications in psychotic disorders.


Conference Paper

BACKGROUND: Patients with psychotic disorders are often treated with numerous medications, many of which have anticholinergic activity. We assessed cognition in relation to the cumulative anticholinergic burden of multiple drugs included in treatment regimens of participants from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study. METHOD: Clinically stable participants with schizophrenia (n=206), schizoaffective disorder (n=131), and psychotic bipolar disorder (n=146) were examined. Anticholinergic properties of all scheduled drugs were quantified using the Anticholinergic Drug Scale (ADS). ADS scores were summed across individual drugs to create a total ADS burden score for each participant and examined in relation to the Brief Assessment of Cognition in Schizophrenia (BACS). RESULTS: Anticholinergic burden aggregated across all medications was inversely related to cognitive performance starting at ADS scores of 4 in participants with schizophrenia. Those with ADS scores ≥4 had lower composite BACS scores compared to those with ADS<4 (p=0.004). Among BACS subtests, Verbal Memory was the most adversely affected by high anticholinergic burden. Despite similar anticholinergic burden scores across groups, a significant threshold effect of anticholinergic burden was not detected in schizoaffective or psychotic bipolar disorder. CONCLUSION: We identified an adverse effect threshold of anticholinergic burden on cognition in clinically stable participants with schizophrenia. This relationship was not identified in affective psychoses. Examination of other medications, doses, and clinical measures did not account for these findings. Patients with schizophrenia may have increased cognitive susceptibility to anticholinergic medications and the aggregate effects of one's medication regimen may be important to consider in clinical practice.

Full Text

Duke Authors

Cited Authors

  • Eum, S; Hill, SK; Rubin, LH; Carnahan, RM; Reilly, JL; Ivleva, EI; Keedy, SK; Tamminga, CA; Pearlson, GD; Clementz, BA; Gershon, ES; Keshavan, MS; Keefe, RSE; Sweeney, JA; Bishop, JR

Published Date

  • December 2017

Published In

Volume / Issue

  • 190 /

Start / End Page

  • 129 - 135

PubMed ID

  • 28390849

Pubmed Central ID

  • 28390849

Electronic International Standard Serial Number (EISSN)

  • 1573-2509

Digital Object Identifier (DOI)

  • 10.1016/j.schres.2017.03.034

Conference Location

  • Netherlands